Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Researchers track Teplizumab's Real-World impact on type 1 diabetes

NCT ID NCT07457580

First seen Mar 21, 2026 · Last updated May 23, 2026 · Updated 8 times

Summary

This study is gathering information from medical records of about 60 people with stage 2 type 1 diabetes who received the drug teplizumab. The goal is to learn more about the patients' health history, how doctors monitor them, and how quickly their diabetes progresses. This is an observational study, meaning researchers are just collecting data, not testing a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number: 3800003

    RECRUITING

    Palermo, 90127, Italy

  • Investigational Site Number: 7240001

    RECRUITING

    Madrid, 28034, Spain

  • Investigational Site Number: 7240002

    RECRUITING

    Madrid, 28046, Spain

  • Investigational Site Number: 8260002

    RECRUITING

    London, E1 1BB, United Kingdom

Conditions

Explore the condition pages connected to this study.